Integrated Drug Discovery Platform for Inborn Error Disorders

EPO published international patent application EP3894578A1 on March 25, 2026, titled 'Integrated Drug Discovery Platform for Inborn Error of Metabolism Disorders.' The application covers methods and compositions for drug discovery related to metabolic disorders, with inventors Gazit Ehud and Laor Dana. IPC classifications include A61K31/122, A61K31/352, C12Q1/02, and various G01N classifications covering diagnostic and screening methods.

This is a patent publication notice with no compliance requirements. Pharmaceutical companies and researchers developing treatments for inborn errors of metabolism should review the patent claims to assess potential licensing needs or freedom-to-operate implications for their own drug development programs.